Stemtech cuts costs, narrows losses but faces $6.4M working capital gap; seeks $5-7M

Stemtech Corporation (PINK: STEK) - Quick operational and financial snapshot from the Form 10‑Q (quarter ended June 30, 2025).

What's happening inside
- Management is executing a restructuring: cutting commissions, selling & marketing, renegotiating vendor contracts and outsourcing fulfillment to reduce costs.
- Product and market moves: launched Cellect One® Shield HOCL and StemPets™ in 2025; pursuing expansion of Independent Business Partner (IBP) network and a Direct‑to‑Consumer (DTC) channel slated to ramp in 2026.
- Capital plan: management is actively pursuing a private placement to raise ~$5-7M by Q4 2025, negotiating a convertible debt facility up to $3M (target Q1 2026), and intends further cost reductions if financing is delayed.
- Financing mix includes notes, convertible debentures, and factoring arrangements. The company continues to rely on equity and debt issuance for cash.

Key facts & figures (as reported)
- Shares outstanding: 146,176,902 shares of common stock (as of August 19, 2025).
- Cash (June 30, 2025): $272,450.
- Current assets (June 30, 2025): $1,095,862. Total assets: $3,872,156.
- Current liabilities (June 30, 2025): $10,323,863. Total liabilities: $10,323,863.
- Working capital / shareholders' deficit: Stockholders' equity (deficit) at June 30, 2025: $(6,451,707). Accumulated deficit: $(32,582,923). Management states a working capital deficiency of approximately $6.4 million.
- Accounts payable & accrued expenses: $5,227,878 (June 30, 2025).
- Notes payable (short‑term): $2,414,829; Convertible debentures, net: $1,725,989; Factoring liability: $856,918 (June 30, 2025).
- Inventory (June 30, 2025): $274,807 (up from $197,355 at 12/31/24).
- Goodwill: $467,409. Intangible assets, net: $2,292,405 (June 30, 2025).

Income statement - positives
- Gross profit (quarter ended 6/30/2025): $552,016 - reflects cost control despite lower sales.
- Cost of goods sold (three months): $145,909 vs $332,177 (Q2 2024) - notable reduction in COGS.
- Total operating expenses (Q2 2025): $853,004 vs $1,685,932 (Q2 2024) - operating expense reduction of $832,928 quarter‑over‑quarter.
- Interest expense fell (three months): $79,727 (Q2 2025) vs $117,364 (Q2 2024), helping improve non‑operating results.
- Net loss improved (three months): $(296,280) vs $(784,087) in Q2 2024 - the company narrowed quarterly losses through spending cuts and financing management.

Income statement - negatives / risks
- Revenue decline: Net sales Q2 2025 $697,925 vs Q2 2024 $1,325,800 (six months: $1,565,971 vs $2,708,370) - material top‑line contraction year‑over‑year.
- Operating loss (Q2): $(300,988); six months operating loss: $(1,505,893).
- Net loss (six months): $(1,755,006) (six months 2024: $(2,204,716)) - recurring losses and negative retained earnings (~$32.6M).
- Reliance on non‑operational financing: factoring and convertible debt are being used to fund working capital; factoring liability $856,918 and convertible notes net $1,725,989 add cash‑flow pressure.
- Cash burn: Net cash used in operating activities for six months ended 6/30/2025: $(635,555). Financing provided $552,134 - operating cash flow remains negative.
- Stock dilution and related‑party financing risks: management has issued stock for services and converted debt to equity historically; related party notes outstanding to executives noted in filings.
- Going concern: company discloses substantial doubt about its ability to continue as a going concern without additional financing.

Other material items to watch
- Management's capital targets: private placement $5-7M by Q4 2025 and a convertible facility up to $3M by Q1 2026 - these are critical to execution and to removing going concern risks.
- Cost reduction targets: management expects to reduce monthly cash operating expenditures by ~$0.5M (≈20%) by end Q3 2025 - monitor actual expense run‑rate improvements.
- Legal accrual: $267,000 accrued for ongoing litigation with former CEO (included in accounts payable).
- Offsetting translation swings: large foreign currency translation adjustments have materially affected comprehensive income in prior periods (watch FX exposure in international segments).
- Dilution risk: additional equity or convertible financings will dilute current shareholders and may include senior preferences.

Bottom line - straight view
- Management has cut costs and reduced losses quarter‑over‑quarter, showing operational discipline; COGS and operating expenses are down and interest costs have eased.
- But revenues have fallen materially, cash remains low ($272k), current liabilities far exceed current assets, and the company relies on debt, factoring and anticipated equity raises to survive. The going concern disclosure is real - success depends on completing the planned financings and executing distributor/DTC growth without further heavy dilution.
- Investors should watch fundraising outcomes, cash runway, actual expense reductions vs targets, and whether revenue stabilization/recovery follows the restructuring moves.

Source: Stemtech Corporation Form 10‑Q for quarter ended June 30, 2025 (filing dated August 19, 2025).